Notably, sensitivity of NB organoids to BCL2 inhibitor venetoclax correlated with mesenchymal expression signature, suggesting that BCL2 inhibition could also target intratumoural heterogeneity [152]. This evidence concerns the gene BCL2 and neuroblastoma.